Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Effecty vs OrderlyMeds

Effecty
Graded #29

Higher grade

vs+11.299999999999997
OrderlyMeds
Graded #78

Lower grade

The verdict

Effecty takes it — 83.7/100 to 72.4/100.

Effecty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOrderlyMeds +12
80
92
Dose & formulationEffecty +20
84
64
Clinical oversightEffecty +3
85
82
Labs & monitoringEffecty +31
84
53
FulfillmentEffecty +22
87
65
Contract termsEffecty +31
86
55
Effecty · left barOrderlyMeds · right bar

The numbers

MetricEffectyOrderlyMeds
WeighScore83.7/10072.4/100
GradeBC
Scorecard rank#29#78
Semaglutide$160/mo$74/mo (starting dose, 2-mo starter plan, new patients only, compounded)
Tirzepatide$240/mo$299/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Effecty

Graded #29 · B

Strengths

  • Brand-name access
  • LegitScript-verified, all 50 states
  • Both molecules

Where it loses points

  • Higher pricing ($160/$240)
  • Injection-only
  • Not a value leader
OrderlyMeds

Graded #78 · C

Strengths

  • The starter rate and the standing rate are both published, so the step-up is visible before signing up
  • No membership fees and no hidden costs, stated as such
  • The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
  • Brand-name routes are priced openly, at retail

Where it loses points

  • The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
  • Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
  • Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard